New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
16:38 EDTKITEKite Pharma announces positive phase 1-2a results, sees 92% objective response
Kite Pharma announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin's lymphoma with an anti-CD19 chimeric antigen receptor, or CAR, T cell therapy. Kite's most advanced product candidate, KTE-C19, is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The findings from an ongoing Phase 1-2a clinical trial funded by Kite and conducted by the Surgery Branch of the National Cancer Institute, or NCI, demonstrated that in 12 out of 13 evaluable patients with advanced B-cell malignancies, administration of anti-CD19 CAR T cells resulted in complete remission in eight patients and partial remission in four patients, representing an overall objective response rate of 92%. Of seven evaluable patients with chemotherapy-refractory Diffuse Large B-cell Lymphomr, or DLBCL, four achieved complete remission, three of which are ongoing with durations ranging from 9 to 22 months. "We are greatly encouraged by the strong results we have seen from our joint lead clinical program with the NCI," commented Arie Belldegrun, Kite's president and CEO. "Based on this substantial progress, Kite plans to file an IND in Q4 of this year to initiate a Phase 1-2 single-arm multicenter clinical trial of KTE-C19 in patients with DLBCL who have failed two or more lines of therapy. We are excited to advance this promising therapy and anticipate commencing patient enrollment in our DLBCL clinical trial in the first half of 2015."
News For KITE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
08:14 EDTKITEKite Pharma announces expanded agreement with Tel Aviv Sourasky Medical Center
Kite Pharma announced that the company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite's most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center's Division of Research and Development.
January 20, 2015
13:21 EDTKITECAR T-Cell therapy drug stocks down sharply following NY Times story
Shares of biotechnology companies that are developing chimeric antigen receptor T cells or CAR T therapy drugs are falling sharply after a New York Times story titled "Riding High, Biotech Firms Remain Wary." WHAT'S NEW: Over the weekend, the New York Times published the story that struck a cautionary tone on the CAR-T therapy drugs. In this form of cancer treatment the patients own immune system cells are genetically manipulated to battle tumors. The New York Times story noted that there were some notable outcomes in the treatment of leukemia and lymphoma with the CAR T treatments but highlighted that the "technique is still early in development and can cause severe side effects." WHAT'S NOTABLE. Early last week, Intrexon (XON) and its oncology partner, ZIOPHARM Oncology (ZIOP), announced an exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sub-licensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. Both companies' shares were up sharply following the announcement ZIOPHARM was up around 55% and Intrexon up over 30% the day following the announcement. PRICE ACTION: Shares of drug companies in the space are sharply lower in midday trading, with ZIOPHARM Oncology and Kite Pharma (KITE) each down over 9%, Intrexon down almost 12%, and Bellicum Pharmaceutical (BLCM) and bluebird bio (BLUE) each down almost 5%. Reference Link
January 19, 2015
15:33 EDTKITEKite Pharma to present on six-day KTE-C19 manufacturing process
Kite Pharma announced presentations on the company's six-day manufacturing process for the production of its lead product candidate, KTE-C19. The manufacturing technology enables a patient's T cells to be genetically modified using a gammaretroviral vector to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias, the company said. Presentations taking place at this week's Scale-Up and Manufacturing of Cell-Based Therapies IV, an Engineering Conferences International conference, being held in San Diego, California, include: Oral Presentation: "Production of autologous T cells for multi-center trials" and "Scale-up and Recovery of a Gammaretroviral Vector."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use